Institutional Fund
Enavate Sciences Gp, LLC
New York, NYCIK 19531075 filings on record
Portfolio Value
$351.51M
Q1 2026
Holdings
7
Reported positions
New Buys
0
Opened this quarter
QoQ Change
-30.6%
from $506.78M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Sionna Therapeutics Inc28.3%
- Immunome Inc22.5%
- Zenas Biopharma Inc21.8%
- Compass Therapeutics Inc11.7%
- Bridgebio Oncology Therapeut6.7%
- Upstream Bio Inc6.3%
- Other2.7%
Portfolio Holdings
7 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Sionna Therapeutics Inc | 2.48M | $99.34M | 28.3% | 0 | Held |
| 2 | Immunome Inc | 3.61M | $79.03M | 22.5% | −1.15M | Reduced |
| 3 | Zenas Biopharma Inc | 3.92M | $76.62M | 21.8% | 0 | Held |
| 4 | Compass Therapeutics Inc | 7.79M | $41.20M | 11.7% | 0 | Held |
| 5 | Bridgebio Oncology Therapeut | 2.63M | $23.51M | 6.7% | 0 | Held |
| 6 | Upstream Bio Inc | 2.46M | $22.14M | 6.3% | 0 | Held |
| 7 | Camp4 Therapeutics Corp | 2.19M | $9.66M | 2.7% | −844.9K | Reduced |